LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells

LTX-315 is a nonameric oncolytic peptide in early clinical development for the treatment of solid malignancies. Preclinical and clinical evidence indicates that the anticancer properties of LTX-315 originate not only from its ability to selectively kill cancer cells, but also from its capacity to pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamazaki, Takahiro, Wennerberg, Erik, Hensler, Michal, Buqué, Aitziber, Kraynak, Jeffrey, Fucikova, Jitka, Zhou, Xi Kathy, Sveinbjørnsson, Baldur, Rekdal, Øystein, Demaria, Sandra, Galluzzi, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366543/
https://www.ncbi.nlm.nih.gov/pubmed/34408925
http://dx.doi.org/10.1080/2162402X.2021.1962592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366543/
https://www.ncbi.nlm.nih.gov/pubmed/34408925
http://dx.doi.org/10.1080/2162402X.2021.1962592

Ejemplares similares